On October 22, 2020 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported that members of management will participate in the Virtual Investor KOL Roundtable on Wednesday, October 28, 2020 at 4:00 PM ET (Press release, Navidea Biopharmaceuticals, OCT 22, 2020, View Source [SID1234568802]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Participating in the KOL Roundtable discussion will be Jed Latkin, Navidea’s Chief Executive Officer and Michael Rosol, Ph.D., Chief Medical Officer of Navidea. Joining the Navidea management team for the discussion will be Jonathan Graf, MD. Dr. Graf is Professor in the Department of Medicine at the University of California San Francisco (UCSF) in the division of rheumatology at Zuckerberg San Francisco General. He is board certified in rheumatology, receiving his MD degree from the University of Pennsylvania and completing his residency and fellowship training at the UCSF School of Medicine. He has been a practicing rheumatologist for nearly 20 years and co-founded the UCSF rheumatoid arthritis (RA) cohort in 2006. He is co-author on numerous publications in the field of rheumatology and has been an investigator on multiple clinical trials related to rheumatoid arthritis. He currently receives research support from Navidea as one of the lead investigators for the NAV3-31 trial in RA, and he has been involved in the design and execution of this and other clinical trials of Tilmanocept in RA.
A live video webcast of the KOL Roundtable will be available on the IR Calendar page of the Investors section of the Company’s website (www.navidea.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.
In addition to the KOL roundtable discussion, members of the management team will be available for one-on-one meetings with qualified members of the investment community. To schedule a one-on-one call with management, please submit a request through the conference website virtualinvestorco.com, or contact the conference at [email protected]. For more information about the event, please visit virtualinvestorco.com.